Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
KSPHF Quote, Financials, Valuation and Earnings
Last price:
$25.77
Seasonality move
:
-2.35%
Day range:
$25.77 - $25.77
52-week range:
$23.23 - $31.90
Dividend yield:
3.03%
P/E ratio:
11.38x
P/S ratio:
1.70x
P/B ratio:
0.77x
Volume:
--
Avg. volume:
4
1-year change:
8.05%
Market cap:
$1.1B
Revenue:
$579.4M
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KSPHF
Kissei Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KSPHF
Kissei Pharmaceutical Co., Ltd.
|
$25.77 | -- | $1.1B | 11.38x | $0.63 | 3.03% | 1.70x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $142.5M | -- | $0.00 | 0% | 21.89x |
|
HLOSF
Healios KK
|
$2.20 | -- | $297M | -- | $0.00 | 0% | 343.65x |
|
PPTDF
PeptiDream Inc.
|
$8.18 | -- | $1.1B | 13.79x | $0.00 | 0% | 8.56x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.28 | -- | $477.8M | -- | $0.00 | 0% | 2.40x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KSPHF
Kissei Pharmaceutical Co., Ltd.
|
0.79% | 0.867 | 0.98% | 3.28x |
|
AMGXF
AnGes, Inc.
|
1.74% | 0.000 | 0.25% | 0.89x |
|
HLOSF
Healios KK
|
34.82% | 2.114 | 7.46% | 1.83x |
|
PPTDF
PeptiDream Inc.
|
27.41% | 1.316 | 7.7% | 1.47x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 0.726 | 73.82% | 1.51x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KSPHF
Kissei Pharmaceutical Co., Ltd.
|
$79.9M | $20.5M | 6.77% | 6.83% | 11.77% | -- |
|
AMGXF
AnGes, Inc.
|
$399.5K | -$10.4M | -153.93% | -162.7% | -703% | -- |
|
HLOSF
Healios KK
|
-$798.3K | -$6.6M | -44.36% | -88.96% | -4043.07% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$17.4M | -$6M | -5.2% | -7.06% | -16.33% | -$2.8M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Kissei Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns KSPHF or AMGXF?
AnGes, Inc. has a net margin of 12.24% compared to Kissei Pharmaceutical Co., Ltd.'s net margin of -190.55%. Kissei Pharmaceutical Co., Ltd.'s return on equity of 6.83% beat AnGes, Inc.'s return on equity of -162.7%.
Company Gross Margin Earnings Per Share Invested Capital KSPHFKissei Pharmaceutical Co., Ltd.45.91% $0.51 $1.4B AMGXFAnGes, Inc.27% -$0.01 $20M -
What do Analysts Say About KSPHF or AMGXF?
Kissei Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kissei Pharmaceutical Co., Ltd. has higher upside potential than AnGes, Inc., analysts believe Kissei Pharmaceutical Co., Ltd. is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSPHFKissei Pharmaceutical Co., Ltd.0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is KSPHF or AMGXF More Risky?
Kissei Pharmaceutical Co., Ltd. has a beta of 0.415, which suggesting that the stock is 58.535% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.039, suggesting its less volatile than the S&P 500 by 96.075%.
-
Which is a Better Dividend Stock KSPHF or AMGXF?
Kissei Pharmaceutical Co., Ltd. has a quarterly dividend of $0.63 per share corresponding to a yield of 3.03%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kissei Pharmaceutical Co., Ltd. pays 36.47% of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend. Kissei Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KSPHF or AMGXF?
Kissei Pharmaceutical Co., Ltd. quarterly revenues are $174M, which are larger than AnGes, Inc. quarterly revenues of $1.5M. Kissei Pharmaceutical Co., Ltd.'s net income of $21.3M is higher than AnGes, Inc.'s net income of -$2.8M. Notably, Kissei Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 11.38x while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kissei Pharmaceutical Co., Ltd. is 1.70x versus 21.89x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSPHFKissei Pharmaceutical Co., Ltd.1.70x 11.38x $174M $21.3M AMGXFAnGes, Inc.21.89x -- $1.5M -$2.8M
-
Which has Higher Returns KSPHF or HLOSF?
Healios KK has a net margin of 12.24% compared to Kissei Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Kissei Pharmaceutical Co., Ltd.'s return on equity of 6.83% beat Healios KK's return on equity of -88.96%.
Company Gross Margin Earnings Per Share Invested Capital KSPHFKissei Pharmaceutical Co., Ltd.45.91% $0.51 $1.4B HLOSFHealios KK-491.87% $0.11 $47.9M -
What do Analysts Say About KSPHF or HLOSF?
Kissei Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Kissei Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Kissei Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings KSPHFKissei Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is KSPHF or HLOSF More Risky?
Kissei Pharmaceutical Co., Ltd. has a beta of 0.415, which suggesting that the stock is 58.535% less volatile than S&P 500. In comparison Healios KK has a beta of 0.237, suggesting its less volatile than the S&P 500 by 76.316%.
-
Which is a Better Dividend Stock KSPHF or HLOSF?
Kissei Pharmaceutical Co., Ltd. has a quarterly dividend of $0.63 per share corresponding to a yield of 3.03%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kissei Pharmaceutical Co., Ltd. pays 36.47% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Kissei Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KSPHF or HLOSF?
Kissei Pharmaceutical Co., Ltd. quarterly revenues are $174M, which are larger than Healios KK quarterly revenues of $162.3K. Kissei Pharmaceutical Co., Ltd.'s net income of $21.3M is higher than Healios KK's net income of $12.4M. Notably, Kissei Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 11.38x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kissei Pharmaceutical Co., Ltd. is 1.70x versus 343.65x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSPHFKissei Pharmaceutical Co., Ltd.1.70x 11.38x $174M $21.3M HLOSFHealios KK343.65x -- $162.3K $12.4M
-
Which has Higher Returns KSPHF or PPTDF?
PeptiDream Inc. has a net margin of 12.24% compared to Kissei Pharmaceutical Co., Ltd.'s net margin of -9.39%. Kissei Pharmaceutical Co., Ltd.'s return on equity of 6.83% beat PeptiDream Inc.'s return on equity of -7.06%.
Company Gross Margin Earnings Per Share Invested Capital KSPHFKissei Pharmaceutical Co., Ltd.45.91% $0.51 $1.4B PPTDFPeptiDream Inc.47.44% -$0.03 $452.8M -
What do Analysts Say About KSPHF or PPTDF?
Kissei Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kissei Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Kissei Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSPHFKissei Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is KSPHF or PPTDF More Risky?
Kissei Pharmaceutical Co., Ltd. has a beta of 0.415, which suggesting that the stock is 58.535% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.786%.
-
Which is a Better Dividend Stock KSPHF or PPTDF?
Kissei Pharmaceutical Co., Ltd. has a quarterly dividend of $0.63 per share corresponding to a yield of 3.03%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kissei Pharmaceutical Co., Ltd. pays 36.47% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Kissei Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KSPHF or PPTDF?
Kissei Pharmaceutical Co., Ltd. quarterly revenues are $174M, which are larger than PeptiDream Inc. quarterly revenues of $36.8M. Kissei Pharmaceutical Co., Ltd.'s net income of $21.3M is higher than PeptiDream Inc.'s net income of -$3.5M. Notably, Kissei Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 11.38x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kissei Pharmaceutical Co., Ltd. is 1.70x versus 8.56x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSPHFKissei Pharmaceutical Co., Ltd.1.70x 11.38x $174M $21.3M PPTDFPeptiDream Inc.8.56x 13.79x $36.8M -$3.5M
-
Which has Higher Returns KSPHF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 12.24% compared to Kissei Pharmaceutical Co., Ltd.'s net margin of -99.41%. Kissei Pharmaceutical Co., Ltd.'s return on equity of 6.83% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital KSPHFKissei Pharmaceutical Co., Ltd.45.91% $0.51 $1.4B SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About KSPHF or SOLTF?
Kissei Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kissei Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Kissei Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KSPHFKissei Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is KSPHF or SOLTF More Risky?
Kissei Pharmaceutical Co., Ltd. has a beta of 0.415, which suggesting that the stock is 58.535% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.021, suggesting its less volatile than the S&P 500 by 97.926%.
-
Which is a Better Dividend Stock KSPHF or SOLTF?
Kissei Pharmaceutical Co., Ltd. has a quarterly dividend of $0.63 per share corresponding to a yield of 3.03%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kissei Pharmaceutical Co., Ltd. pays 36.47% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Kissei Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KSPHF or SOLTF?
Kissei Pharmaceutical Co., Ltd. quarterly revenues are $174M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. Kissei Pharmaceutical Co., Ltd.'s net income of $21.3M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, Kissei Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 11.38x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kissei Pharmaceutical Co., Ltd. is 1.70x versus 2.40x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSPHFKissei Pharmaceutical Co., Ltd.1.70x 11.38x $174M $21.3M SOLTFNxera Pharma Co., Ltd.2.40x -- $50.4M -$50.1M
-
Which has Higher Returns KSPHF or STMM?
Stemcell Holdings, Inc. has a net margin of 12.24% compared to Kissei Pharmaceutical Co., Ltd.'s net margin of --. Kissei Pharmaceutical Co., Ltd.'s return on equity of 6.83% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSPHFKissei Pharmaceutical Co., Ltd.45.91% $0.51 $1.4B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About KSPHF or STMM?
Kissei Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kissei Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Kissei Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSPHFKissei Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is KSPHF or STMM More Risky?
Kissei Pharmaceutical Co., Ltd. has a beta of 0.415, which suggesting that the stock is 58.535% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KSPHF or STMM?
Kissei Pharmaceutical Co., Ltd. has a quarterly dividend of $0.63 per share corresponding to a yield of 3.03%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kissei Pharmaceutical Co., Ltd. pays 36.47% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Kissei Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios KSPHF or STMM?
Kissei Pharmaceutical Co., Ltd. quarterly revenues are $174M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Kissei Pharmaceutical Co., Ltd.'s net income of $21.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Kissei Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 11.38x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kissei Pharmaceutical Co., Ltd. is 1.70x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSPHFKissei Pharmaceutical Co., Ltd.1.70x 11.38x $174M $21.3M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
